Beta

Maze therapeutics, inc.MAZE.US Overview

US StockHealthcare
(No presentation for MAZE)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

MAZE AI Insights

MAZE Overall Performance

MAZE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MAZE Recent Performance

-1.35%

Maze therapeutics, inc.

-1.64%

Avg of Sector

-0.21%

S&P500

MAZE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check MAZE's Trend

MAZE Key Information

MAZE Valuation Metrics

MAZE Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Price of MAZE

MAZE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MAZE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.17
PE Ratio (TTM)
-
Forward PE
8.53
PS Ratio (TTM)
501.65
PB Ratio
4.01
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2173.24%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.17
PE Ratio (TTM)
-
Forward PE
8.53
PS Ratio (TTM)
501.65
PB Ratio
4.01
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2173.24%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is MAZE's latest earnings report released?

    The most recent financial report for Maze therapeutics, inc. (MAZE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MAZE's short-term business performance and financial health. For the latest updates on MAZE's earnings releases, visit this page regularly.

  • How much debt does MAZE have?

    As of the end of the reporting period, Maze therapeutics, inc. (MAZE) had total debt of 23.31M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MAZE have?

    At the end of the period, Maze therapeutics, inc. (MAZE) held Total Cash and Cash Equivalents of 190.34M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MAZE's EPS continuing to grow?

    According to the past four quarterly reports, Maze therapeutics, inc. (MAZE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MAZE?

    Maze therapeutics, inc. (MAZE)'s Free Cash Flow (FCF) for the period is -27.76M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 20.41% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MAZE?

    The latest valuation data shows Maze therapeutics, inc. (MAZE) has a Price-To-Earnings (PE) ratio of -12.03 and a Price/Earnings-To-Growth (PEG) ratio of -0.4. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.